Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $300,978.72 in Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 18,648 shares of Momenta Pharmaceuticals stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $16.14, for a total transaction of $300,978.72. Following the completion of the sale, the chief executive officer now owns 258,713 shares in the company, valued at $4,175,627.82. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Craig A. Wheeler also recently made the following trade(s):

  • On Tuesday, November 21st, Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.35, for a total transaction of $54,948.60.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded up $0.25 during trading on Wednesday, hitting $16.25. 934,334 shares of the stock traded hands, compared to its average volume of 927,496. The firm has a market cap of $1,245.11, a price-to-earnings ratio of -20.31 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a one year low of $11.85 and a one year high of $19.46.

Several brokerages have issued reports on MNTA. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday. Stifel Nicolaus reiterated a “hold” rating and issued a $18.00 price target on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. Cowen set a $15.00 price target on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a research note on Wednesday, November 1st. Finally, Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. Momenta Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $15.30.

Several institutional investors have recently added to or reduced their stakes in MNTA. Ameritas Investment Partners Inc. increased its stake in shares of Momenta Pharmaceuticals by 14.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 834 shares during the last quarter. LS Investment Advisors LLC increased its stake in shares of Momenta Pharmaceuticals by 59.8% during the 4th quarter. LS Investment Advisors LLC now owns 9,300 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 3,479 shares during the last quarter. Amalgamated Bank acquired a new position in shares of Momenta Pharmaceuticals during the 4th quarter worth about $152,000. Landscape Capital Management L.L.C. acquired a new position in shares of Momenta Pharmaceuticals during the 4th quarter worth about $159,000. Finally, Citigroup Inc. increased its stake in shares of Momenta Pharmaceuticals by 263.2% during the 2nd quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock worth $232,000 after purchasing an additional 9,954 shares during the last quarter. Institutional investors own 93.01% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/momenta-pharmaceuticals-inc-mnta-ceo-sells-300978-72-in-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply